Early detection of prostate cancer at precise levels serves as the basis for successful medical treatments, along with better patient recovery success, since prostate cancer is a leading type of cancer in adult males within global populations. The combination of prostate-specific antigen (PSA) testing with digital rectal examinations and biopsies produces many inaccurate positive results in addition to poor specificity by intruding on bodily tissues. Biosensing technology platforms from recent times enable simultaneous PSA detection, together with prostate cancer antigen 3 analysis, circulating tumor cell count, and analysis of microRNA and exosomes, while maintaining higher detection sensitivity with precise performance. The subsequent section provides a detailed breakdown of biosensor bases and technical components, including research on electrochemical, optical, piezoelectric, and thermal transduction elements. Nanomaterials combined with microfluidic systems and artificial intelligence (AI) enable fast and efficient diagnosis service delivery with minimal sample requirements. Analysis of current biosensing solutions involves translating between emerging biomarkers, while the chapter describes modern technological biosensors, including smartphone systems and wearable devices. The current analysis by the chapter presents issues related to reproducibility and requirements for clinical validation and authorized approval before examining potential advancements in precise oncology AI-based individualized diagnostic solutions. The chapter demonstrates how biomedical engineering technology, combined with nanotechnology protocols, can transform clinical oncology science into developing advanced diagnostic pathways for prostate cancer, laying the foundation for personalized medical approaches.